Gilead Sciences Inc (GILD) — closed signal from April 20, 2026
Partial Published before the outcome was known, scored automatically when the window closed on July 19, 2026.
Predicted vs. what happened
GILD price · publication thesis → realized outcomesplit-adjusted
$132.26 – $137.19Entry zone — fair-value band
$136.27Published — price the day we called it
$151.63Target — the price the thesis aimed for
$140.61Peak — highest point inside the window, not a realized return
$134.28Window close — end-of-window price, context only
What happened
Partial
Reached 27% of the predicted growth at its peak, without hitting the target.
Peak price
$140.61
peak on July 17, 2026 — not a realized returnPeak gain
+3.2%
peak, from the publication priceWindow close
$134.28
end-of-window price, context onlyDays to target
—
Window
April 20, 2026 – July 19, 2026
The thesis — published April 20, 2026
Predicted growth
+12%
over the measurement windowTarget price
$151.63
the price the thesis aimed forEntry zone
$132.26 – $137.19
the fair-value band we waited forPrice at publication
$136.27
published April 20, 2026Confidence
76%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Gilead mixes steady profits with near-term opportunities in cancer drugs and HIV. Recent updates on expanded cancer programs, efforts to broaden access to lenacapavir, and a raised price target make the short-term picture more positive. The stock is rebounding from weakness and the outlook does not rely on a broad biotech rally.
Primary drivers
- New cancer program expansion widens future drug options
- Efforts to broaden lenacapavir access strengthen HIV story
- Strong profits help the stock weather downturns
- Lowered share levels make recovery more plausible
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.